Pharmaco-mechanic antithrombotic strategies to reperfusion of the infarct-related artery in patients with ST-elevation acute myocardial infarctions
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
PubMed
23408112
PubMed Central
PMC3650237
DOI
10.1007/s12265-013-9448-1
Knihovny.cz E-zdroje
- MeSH
- čas zasáhnout při rozvinutí nemoci MeSH
- fibrinolytika škodlivé účinky terapeutické užití MeSH
- infarkt myokardu diagnóza etiologie terapie MeSH
- inhibitory agregace trombocytů škodlivé účinky terapeutické užití MeSH
- koronární angioplastika * přístrojové vybavení MeSH
- lidé MeSH
- mechanická trombolýza * škodlivé účinky MeSH
- nemoci koronárních tepen komplikace diagnóza terapie MeSH
- rizikové faktory MeSH
- stenty MeSH
- trombektomie škodlivé účinky metody MeSH
- trombolytická terapie * škodlivé účinky MeSH
- výběr pacientů MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- fibrinolytika MeSH
- inhibitory agregace trombocytů MeSH
Primary percutaneous coronary intervention is the best treatment of patients with ST elevation myocardial infarction (STEMI). When managing a STEMI patient, our approach must be rapid and aggresive in order to interrupt the pathological process of thrombus formation and stabilization. The therapy must be initiated prior to angiography (pretreatment), continued during the procedure (periprocedural), recovery phase (in-hospital), and follow-up. The treatment strategies resulting in thrombus dissolution/extraction have focused on optimization of both pharmacological and interventional therapies. At present, there is no optimal evidence-based approach to all patients with STEMI, and the treatment of these patients needs to be modified with respect to the risk profile, availability of medical resources, and our experience. In this review, we summarize current pharmacological and interventional strategies used in the setting of STEMI and discuss potential benefits of novel dosing regimens and combinations of drugs and techniques.
Zobrazit více v PubMed
Steg P, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) European Heart Journal. 2012;33:2569–2619. doi: 10.1093/eurheartj/ehs289. PubMed DOI
Topol E, Califf R, Van De Werf F, et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The New England Journal of Medicine. 1993;329:673–682. doi: 10.1056/NEJM199307223290401. PubMed DOI
Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England Journal of Medicine. 2006;354:1477–1488. doi: 10.1056/NEJMoa060898. PubMed DOI
Silvain, J., Beygui F., Barthelemy O. et al.(2012). Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ, (Clinical research ed ), 344:e553. PubMed PMC
Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. Circulation. 1998;98:1597–1603. doi: 10.1161/01.CIR.98.16.1597. PubMed DOI
Chen Z, Jiang L. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet. 2005;366:1607–1621. doi: 10.1016/S0140-6736(05)67660-X. PubMed DOI
Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine. 2005;352:1179–1189. doi: 10.1056/NEJMoa050522. PubMed DOI
Mangiacapra F, Muller O, Ntalianis A, et al. Comparison of 600 versus 300-mg clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. The American Journal of Cardiology. 2010;106:1208–1211. doi: 10.1016/j.amjcard.2010.06.044. PubMed DOI
Patti G, Barczi G, Orlic D, et al. Outcome comparison of 600- and 300-mg Loading Doses of Clopidogrel in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Results From the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Myocardial Infarction) Randomized Study. Journal of the American College of Cardiology. 2011;58:1592–1599. doi: 10.1016/j.jacc.2011.06.044. PubMed DOI
Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010;376:1233–1243. doi: 10.1016/S0140-6736(10)61088-4. PubMed DOI
Bonello L, Armero S, Ait Mokhtar O, et al. Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. Journal of the American College of Cardiology. 2010;56:1630–1636. doi: 10.1016/j.jacc.2010.07.004. PubMed DOI
Xie HG, Zou JJ, Hu ZY, Zhang JJ, Ye F, Chen SL. Individual variability in the disposition of and response to clopidogrel: Pharmacogenomics and beyond. Pharmacology and Therapeutics. 2011;129:267–289. doi: 10.1016/j.pharmthera.2010.10.001. PubMed DOI
Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation. American Heart Journal. 2007;153:9–16. doi: 10.1016/j.ahj.2006.10.010. PubMed DOI
Montalescot G. Benefits for specific subpopulations in TRITON-TIMI 38. European Heart Journal Supply. 2009;11:G18–G24. doi: 10.1093/eurheartj/sup038. DOI
Alexopoulos D, Galati A, Xanthopoulou I, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. Journal of the American College of Cardiology. 2012;60:193–199. doi: 10.1016/j.jacc.2012.03.050. PubMed DOI
Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial subgroup analysis. Circulation. 2010;122:2131–2141. doi: 10.1161/CIRCULATIONAHA.109.927582. PubMed DOI
Centurion OA. Actual role of platelet glycoprotein IIb/IIIa receptor inhibitors as adjunctive pharmacological therapy to primary angioplasty in acute myocardial infarction: In the light of recent randomized trials and observational studies with bivalirudin. The Open Cardiovascular Medicine Journal. 2010;4:135–145. doi: 10.2174/1874192401004010135. PubMed DOI PMC
Montalescot G, Antoniucci D, Kastrati A, et al. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients' data with long-term follow-up. European Heart Journal. 2007;28:443–449. doi: 10.1093/eurheartj/ehl472. PubMed DOI
De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. The Journal of the American Medical Association. 2005;293:1759–1765. doi: 10.1001/jama.293.14.1759. PubMed DOI
Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: Results of the EVA-AMI trial. Journal of the American College of Cardiology. 2010;56:463–469. doi: 10.1016/j.jacc.2009.08.093. PubMed DOI
Valgimigli M, Biondi-Zoccai G, Tebaldi M, et al. Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: A meta-analysis of randomized trials. European Heart Journal. 2010;31:35–49. doi: 10.1093/eurheartj/ehp376. PubMed DOI
Friedland S, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome. The American Journal of Cardiology. 2011;108:1244–1251. doi: 10.1016/j.amjcard.2011.06.039. PubMed DOI
Gu YL, Kampinga MA, Wieringa WG, et al. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: The comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) Trial. Circulation. 2010;122:2709–2717. doi: 10.1161/CIRCULATIONAHA.110.002741. PubMed DOI
Desch S, Siegemund A, Scholz U, et al. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. Clinical Research in Cardiology. 2012;101:117–124. doi: 10.1007/s00392-011-0372-6. PubMed DOI
Lee MS, Liao H, Yang T, et al. Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: A meta-analysis of randomized clinical trials. International Journal of Cardiology. 2011;152:369–374. doi: 10.1016/j.ijcard.2010.08.007. PubMed DOI
Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: The INFUSE-AMI randomized trial. The Journal of the American Medical Association. 2012;307:1817–1826. doi: 10.1001/jama.2012.421. PubMed DOI
De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials [abstract] International Journal of Cardiology. 2008;126:37–44. doi: 10.1016/j.ijcard.2007.03.112. PubMed DOI
Mehta RH, Harjai KJ, Cox DA, et al. Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [abstract] The American Journal of Cardiology. 2005;96:901–906. doi: 10.1016/j.amjcard.2005.05.044. PubMed DOI
Loubeyre C, Morice MC, Lefevre T, et al. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. Journal of the American College of Cardiology. 2002;39:15–21. doi: 10.1016/S0735-1097(01)01701-6. PubMed DOI
De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. International Journal of Cardiology. 2009;133:213–222. doi: 10.1016/j.ijcard.2007.12.040. PubMed DOI
Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 1927;380:1482–1490. doi: 10.1016/S0140-6736(12)61223-9. PubMed DOI
Dudek D, Dziewierz A, Rzeszutko L, et al. Mesh covered stent in ST-segment elevation myocardial infarction. EuroIntervention. 2010;6:582–589. doi: 10.4244/EIJV6I5A98. PubMed DOI
Stone GW, Abizaid A, Silber S, et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate Micronet MeshGÇôCovered Stent (MGuard) in ST-segment elevation myocardial infarction: The MASTER Trial. Journal of the American College of Cardiology. 2012;60:1975–1984. doi: 10.1016/j.jacc.2012.09.004. PubMed DOI
Sianos G, Papafaklis MI, Daemen J, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. Journal of the American College of Cardiology. 2007;50:573–583. doi: 10.1016/j.jacc.2007.04.059. PubMed DOI
Kushner FG, Hand M, Smith SC, Jr, et al. Focused Updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2009;54:2205–2241. doi: 10.1016/j.jacc.2009.10.015. PubMed DOI
Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. The New England Journal of Medicine. 2008;358:557–567. doi: 10.1056/NEJMoa0706416. PubMed DOI
Vlaar PJ, Svilaas T, van der Horst IC, et al. Cardiac death and reinfarction after 1 year in the thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS): A 1-year follow-up study. Lancet. 2008;371:1915–1920. doi: 10.1016/S0140-6736(08)60833-8. PubMed DOI
Sardella G, Mancone M, Canali E, et al. Impact of thrombectomy with EXPort Catheter in Infarct-Related Artery during primary percutaneous coronary intervention (EXPIRA Trial) on cardiac death [abstract] The American Journal of Cardiology. 2010;106:624–629. doi: 10.1016/j.amjcard.2010.04.014. PubMed DOI
Ali A, Cox D, Dib N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study. Journal of the American College of Cardiology. 2006;48:244–252. doi: 10.1016/j.jacc.2006.03.044. PubMed DOI
Migliorini A, Stabile A, Rodriguez AE, et al. Comparison of AngioJet rheolytic thrombectomy before direct infarct artery stenting with direct stenting alone in patients with acute myocardial infarction: The JETSTENT Trial. Journal of the American College of Cardiology. 2010;56:1298–1306. doi: 10.1016/j.jacc.2010.06.011. PubMed DOI
Lefevre T, Garcia E, Reimers B, et al. X-Sizer for thrombectomy in acute myocardial infarction improves ST-segment resolution: Results of the X-Sizer in AMI for Negligible Embolization and Optimal ST Resolution (X AMINE ST) Trial. Journal of the American College of Cardiology. 2005;46:246–252. doi: 10.1016/j.jacc.2005.04.031. PubMed DOI
Vink MA, Patterson MS, Etten J, et al. A randomized comparison of manual versus mechanical thrombus removal in primary percutaneous coronary intervention in the treatment of ST-segment elevation myocardial infarction (TREAT-MI) Catheterization and Cardiovascular Interventions. 2011;78:14–19. doi: 10.1002/ccd.22932. PubMed DOI
Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: An individual patient-data pooled analysis of 11 trials. European Heart Journal. 2009;30:2193–2203. doi: 10.1093/eurheartj/ehp348. PubMed DOI
Mongeon FP, Belisle P, Joseph L, Eisenberg MJ, Rinfret S. Adjunctive thrombectomy for acute myocardial infarction/clinical perspective. Circulation: Cardiovasc Intervent. 2010;3:6–16. doi: 10.1161/CIRCINTERVENTIONS.109.904037. PubMed DOI
Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: Description of the current situation in 30 countries. European Heart Journal. 2010;31:943–957. doi: 10.1093/eurheartj/ehp492. PubMed DOI PMC